These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 16981971

  • 1. Thiazolidinediones, insulin resistance and obesity: Finding a balance.
    Wilding J.
    Int J Clin Pract; 2006 Oct; 60(10):1272-80. PubMed ID: 16981971
    [Abstract] [Full Text] [Related]

  • 2. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G.
    J Diabetes Complications; 2005 Oct; 19(3):168-77. PubMed ID: 15866064
    [Abstract] [Full Text] [Related]

  • 3. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC.
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [Abstract] [Full Text] [Related]

  • 4. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.
    Moore GB, Pickavance LC, Briscoe CP, Clapham JC, Buckingham RE, Wilding JP.
    Diabetes Obes Metab; 2008 Mar; 10(3):251-63. PubMed ID: 18269641
    [Abstract] [Full Text] [Related]

  • 5. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V, Viswanathan P.
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [Abstract] [Full Text] [Related]

  • 6. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE, Hanna A.
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [Abstract] [Full Text] [Related]

  • 7. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A.
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [Abstract] [Full Text] [Related]

  • 8. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA.
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [Abstract] [Full Text] [Related]

  • 9. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
    Rosenberg DE, Jabbour SA, Goldstein BJ.
    Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
    [Abstract] [Full Text] [Related]

  • 10. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?
    Lindberg M, Astrup A.
    Obes Rev; 2007 Sep; 8(5):381-4. PubMed ID: 17716295
    [Abstract] [Full Text] [Related]

  • 11. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 12. Diabetes medications and body weight.
    Mitri J, Hamdy O.
    Expert Opin Drug Saf; 2009 Sep; 8(5):573-84. PubMed ID: 19538102
    [Abstract] [Full Text] [Related]

  • 13. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.
    Wyne KL.
    Diabetes Obes Metab; 2006 Jul; 8(4):365-80. PubMed ID: 16776743
    [Abstract] [Full Text] [Related]

  • 14. Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
    Russell-Jones D, Khan R.
    Diabetes Obes Metab; 2007 Nov; 9(6):799-812. PubMed ID: 17924864
    [Abstract] [Full Text] [Related]

  • 15. Effect of thiazolidinediones on body weight in patients with diabetes mellitus.
    Fonseca V.
    Am J Med; 2003 Dec 08; 115 Suppl 8A():42S-48S. PubMed ID: 14678865
    [Abstract] [Full Text] [Related]

  • 16. Current treatment of non-alcoholic fatty liver disease.
    Ahmed MH, Byrne CD.
    Diabetes Obes Metab; 2009 Mar 08; 11(3):188-95. PubMed ID: 18564173
    [Abstract] [Full Text] [Related]

  • 17. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk.
    Peters AL.
    Cleve Clin J Med; 2009 Dec 08; 76 Suppl 5():S20-7. PubMed ID: 19952300
    [Abstract] [Full Text] [Related]

  • 18. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B, Lund SS, Vaag A.
    Ugeskr Laeger; 2009 May 04; 171(19):1598-602. PubMed ID: 19419642
    [Abstract] [Full Text] [Related]

  • 19. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR, Cha R, Brown MB, Jaber LA.
    Ann Pharmacother; 2008 Nov 04; 42(11):1541-51. PubMed ID: 18957626
    [Abstract] [Full Text] [Related]

  • 20. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
    Lebovitz HE.
    J Indian Med Assoc; 2008 Nov 04; 106(11):724-6. PubMed ID: 19368098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.